- Home
- DYAI vs MRKR Comparison
DYAI vs MRKR Comparison
Compare DYAI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- MRKR
- Stock Information
- Founded
- DYAI 1979
- MRKR N/A
- Country
- DYAI United States
- MRKR United States
- Employees
- DYAI N/A
- MRKR N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- MRKR Health Care
- Exchange
- DYAI Nasdaq
- MRKR Nasdaq
- Market Cap
- DYAI 31.5M
- MRKR 35.8M
- IPO Year
- DYAI 2004
- MRKR N/A
- Fundamental
- Price
- DYAI $1.13
- MRKR $3.03
- Analyst Decision
- DYAI Strong Buy
- MRKR Strong Buy
- Analyst Count
- DYAI 1
- MRKR 1
- Target Price
- DYAI $6.00
- MRKR $19.00
- AVG Volume (30 Days)
- DYAI 18.7K
- MRKR 36.2K
- Earning Date
- DYAI 11-12-2024
- MRKR 11-22-2024
- Dividend Yield
- DYAI N/A
- MRKR N/A
- EPS Growth
- DYAI N/A
- MRKR N/A
- EPS
- DYAI N/A
- MRKR N/A
- Revenue
- DYAI $3,364,548.00
- MRKR $5,395,849.00
- Revenue This Year
- DYAI $2.04
- MRKR $35.94
- Revenue Next Year
- DYAI $110.34
- MRKR N/A
- P/E Ratio
- DYAI N/A
- MRKR N/A
- Revenue Growth
- DYAI 13.82
- MRKR 79.04
- 52 Week Low
- DYAI $0.93
- MRKR $2.44
- 52 Week High
- DYAI $2.67
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- DYAI 52.65
- MRKR 39.27
- Support Level
- DYAI $1.02
- MRKR $3.52
- Resistance Level
- DYAI $1.23
- MRKR $3.90
- Average True Range (ATR)
- DYAI 0.09
- MRKR 0.40
- MACD
- DYAI 0.01
- MRKR -0.12
- Stochastic Oscillator
- DYAI 52.33
- MRKR 0.00
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.